Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Geron (GERN) EBITDA (2016 - 2025)

Geron's EBITDA history spans 16 years, with the latest figure at -$25.5 million for Q4 2025.

  • For Q4 2025, EBITDA fell 27.38% year-over-year to -$25.5 million; the TTM value through Dec 2025 reached -$68.6 million, up 60.52%, while the annual FY2025 figure was -$68.6 million, 60.52% up from the prior year.
  • EBITDA for Q4 2025 was -$25.5 million at Geron, down from -$13.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.5 million in Q2 2025 and bottomed at -$69.3 million in Q2 2024.
  • The 5-year median for EBITDA is -$28.8 million (2021), against an average of -$34.4 million.
  • The largest annual shift saw EBITDA crashed 85.7% in 2023 before it skyrocketed 82.04% in 2025.
  • A 5-year view of EBITDA shows it stood at -$31.0 million in 2021, then crashed by 35.4% to -$42.0 million in 2022, then decreased by 29.41% to -$54.3 million in 2023, then soared by 63.07% to -$20.0 million in 2024, then fell by 27.38% to -$25.5 million in 2025.
  • Per Business Quant, the three most recent readings for GERN's EBITDA are -$25.5 million (Q4 2025), -$13.9 million (Q3 2025), and -$12.5 million (Q2 2025).